Core Viewpoint - The current valuation of the pharmaceutical sector is at a low level, with public funds (excluding pharmaceutical funds) having low allocation to the sector. Considering the positive recovery of macroeconomic factors such as US Treasury rates, the industry is expected to experience growth by 2025, with various investment opportunities emerging [12][20]. Market Review - The CITIC Pharmaceutical Index decreased by 0.79%, underperforming the CSI 300 Index by 2.02 percentage points, ranking last among 30 primary industries [9]. - The top ten stocks by increase this week included Nanxin Pharmaceutical, Haichen Pharmaceutical, and Sainuo Medical, with increases ranging from 22.45% to 42.48%. Conversely, the top ten stocks by decrease included Nanmo Biological and Qizheng Tibetan Medicine, with decreases ranging from -13.50% to -16.11% [6][9]. Industry and Stock Events - The brain-computer interface (BCI) market is expected to grow significantly, with the global market size projected to increase from $1.2 billion in 2019 to $7.63 billion by 2029, reflecting a CAGR of 25.2% [20][21]. - In China, the BCI market is anticipated to grow from 1 billion yuan in 2020 to 10.5 billion yuan by 2029, with a CAGR of 35.5% [20][22]. - Non-invasive BCIs currently dominate the market, accounting for 78% of the global BCI market share, while medical applications represent over 60% of the downstream application scenarios [15][16]. Investment Themes - The pharmaceutical industry is expected to see a shift from quantity to quality in the innovative drug sector, emphasizing differentiated and internationalized pipelines by 2025 [12]. - The medical device sector is witnessing a recovery in bidding volumes for imaging equipment, with a focus on home medical devices and orthopedic procurement [12]. - The innovation chain (CXO + life sciences services) is anticipated to experience a rebound in investment, with a gradual return to high growth by 2025 [12]. Brain-Computer Interface Industry Update - The BCI industry is characterized by three main types: invasive, semi-invasive, and non-invasive, with non-invasive being the most prevalent due to its safety and ease of use [17][18]. - The Chinese BCI market is still in its early stages, with many companies yet to enter a competitive phase, and the clinical registration numbers are led by companies like Pinchi Medical and Zhejiang Yiyang [29][30]. Policy Support - National and local policies are increasingly supporting the BCI industry, with various departments releasing guidelines to promote innovation and application in the field [23][24].

Investment Rating - The report maintains an optimistic outlook on the pharmaceutical industry, particularly for 2025, suggesting a potential for diverse investment opportunities as the sector is currently undervalued [9]. Core Insights - The brain-computer interface (BCI) market is expected to grow significantly, with a projected global market size of $7.63 billion by 2029, reflecting a CAGR of 25.2% from 2023 to 2029 [21]. - The Chinese BCI market is anticipated to reach 10.5 billion yuan by 2029, with a CAGR of 35.5% from 2023 to 2029 [21]. - The report highlights the increasing support from national and local policies aimed at accelerating the development of the BCI industry, including funding for research and standardization efforts [20]. Summary by Sections Market Overview - The BCI technology is categorized into invasive, semi-invasive, and non-invasive types, with non-invasive BCI currently dominating the market, accounting for 78% of the global market share [17][14]. - The medical sector is identified as the primary application area for BCI technology, with over 60% of the market demand coming from healthcare applications [17]. Industry Events - The report outlines various supportive policies from the government, including the establishment of a standardization committee for BCI technology and specific pricing guidelines for BCI-related medical services [18][19]. Company Analysis - Several companies are highlighted for their advancements in the BCI field, including: - **Xiangyu Medical**: Focused on rehabilitation BCIs with a wide range of product configurations and a strong R&D pipeline [30]. - **Chengyi Tong**: Engaged in both invasive and non-invasive BCI technologies, with recent product launches aimed at the consumer market [30]. - **Weisi Medical**: Specializes in non-invasive BCIs and has a robust patent portfolio related to BCI technologies [31]. - **Milan De**: Develops brain-machine interface systems for rehabilitation, integrating advanced technologies for neurological disorders [32]. Investment Opportunities - The report suggests that the BCI industry is still in its early stages in China, with significant growth potential as competition remains limited [24]. - The pharmaceutical sector is advised to focus on innovative drugs and medical devices, with a recommendation to invest in companies with strong R&D capabilities and market positioning [9][33].

Core Insights - The Guangdong Province is focusing on enhancing its biopharmaceutical and health industry through innovation and policy support, aiming to build global competitiveness in this sector [1] Policy Discussion - Guangdong's biopharmaceutical innovation policy is characterized by "full-chain empowerment" and "institutional openness," with significant reforms such as reducing the review time for Class II medical devices by 50% [3] - Despite favorable policies, companies face challenges in clinical research due to insufficient public hospital bed availability and conservative bank credit [3] - The Guangdong Provincial Drug Administration is seen as proactive and supportive in helping companies navigate regulatory processes [5] Funding Insights - There is a strong demand for long-term investment support from government funds and private capital in the biopharmaceutical sector, as the development cycle is lengthy [9] - The investment cycle for innovative drugs is long, and there is a call for the introduction of long-term capital models to better align with the needs of biopharmaceutical companies [11] - Investment institutions are encouraged to provide not only funding but also systematic support and understanding of the industry's long cycles [13] Transformation and Innovation - There is a notable lack of high-quality research outcomes that meet industry needs, prompting calls for reform in the current research evaluation system [15] - The transition from scientific research to commercial application is challenging, requiring solutions to both technical and market pressures [17] - Collaboration among medical, educational, and research sectors is essential for the development of the biopharmaceutical industry [19] International Expansion - Chinese biopharmaceutical companies are increasingly engaging in business development (BD) transactions, with 40% of significant deals in the first seven months of the year involving Chinese firms, up from 4-5% four years ago [21] - This trend indicates a growing international interest in Chinese innovative drugs and suggests that BD transactions are becoming a viable exit strategy for companies [21] AI and Technology Impact - AI is transforming the internet healthcare and biopharmaceutical sectors by enhancing efficiency and collaboration, although challenges such as data silos remain [23] Company Transformation - Traditional pharmaceutical companies in Guangdong are increasingly focusing on innovation, with one company reporting that 22.4% of its revenue was reinvested in R&D last year [26]

Group 1 - On August 8, several stocks including Hutchison Whampoa, Nanjing Panda Electronics, Oriental Selection, Fubo Group, Zai Ding Pharmaceutical, and Huitongda Network made their debut on the Hong Kong Stock Connect active trading list for the first time in a month [1][2] - The total trading volume of active stocks on August 8 reached 33.757 billion HKD, accounting for 27.32% of the total trading amount on that day, with a net buying amount of 1.614 billion HKD [1] - Among the active stocks, SMIC had the highest trading volume at 11.074 billion HKD, followed by Alibaba and Xiaomi with trading amounts of 3.887 billion HKD and 3.800 billion HKD respectively [1] Group 2 - Hutchison Whampoa had a trading volume of 0.958 billion HKD with a net selling of 0.158 billion HKD, closing down 15.99% [2] - Nanjing Panda Electronics recorded a trading volume of 1.075 billion HKD with a net selling of 0.025 billion HKD, closing down 10.40% [2] - Oriental Selection had a trading volume of 1.024 billion HKD with a net buying of 0.056 billion HKD, closing up 12.32% [2] - Fubo Group had a trading volume of 0.747 billion HKD with a net buying of 0.031 billion HKD, closing up 18.36% [2] - Zai Ding Pharmaceutical had a trading volume of 0.768 billion HKD with a net buying of 0.217 billion HKD, closing down 10.47% [2] - Huitongda Network had a trading volume of 1.758 billion HKD with a net buying of 0.076 billion HKD, closing up 26.90% [2]

| 01797 | 东方甄选 | 港股通 | 102368.82 | 5557.01 | 12.32 | | --- | --- | --- | --- | --- | --- | | | | (沪) | | | | | 00013 | 和黄医药 | 港股通 (深) | 95791.00 | -15806.73 | -15.99 | | 02228 | 晶泰控股 | 港股通 (沪) | 95637.85 | 4462.41 | -2.07 | | 09926 | 康方生物 | 港股通 (深) | 89299.00 | 20184.68 | 1.91 | | 09688 | 再鼎医药 | 港股通 (深) | 76762.00 | 21660.26 | -10.47 | | 01801 | 信达生物 | 港股通 (深) | 75931.00 | 7454.43 | -0.16 | | 03738 | 阜博集团 | 港股通 (深) | 74650.00 | 3149.65 | 18.36 | | 02800 | 盈富基金 | 港股通 (深) | 72894.00 | 68396.01 | -0.70 | 成交活跃股 ...

Market Overview - The Hong Kong stock market experienced a decline of 0.89%, attributed to internal structural issues despite positive market sentiment [1] - Concerns about "stagflation" in the US economy were highlighted, with initial jobless claims rising to 226,000, exceeding economists' expectations of 221,000 [1] - The US added 73,000 jobs in July, below the expected 100,000, while the personal consumption expenditure inflation rate rose to 2.6% year-on-year in June, higher than the anticipated 2.5% [1] Company Performance - Crocs projected a revenue decline of 9% to 11% for Q3, leading to a nearly 30% drop in its stock price, marking its lowest point in three years [1] - Semiconductor companies like SMIC and Hua Hong Semiconductor reported better-than-expected Q2 results, with SMIC's Q3 revenue guidance indicating a 5-7% increase and Hua Hong's a 11.3% increase [2] - AI application company Mingyuan Cloud turned a profit of 12.09 million to 15.41 million RMB, recovering from a loss of 115.37 million RMB last year, driven by product optimization and AI technology [3] Sector Insights - The pharmaceutical sector showed mixed results, with companies like Rongchang Bio and Junshi Biosciences seeing stock increases of over 6%, while Hutchison China MediTech's stock fell nearly 16% despite a significant profit increase due to asset sales [3] - The real estate sector in Hong Kong faced caution, with Wharf Holdings expressing a pessimistic outlook on retail rental prospects, resulting in an 8% stock drop [4] - Gold stocks remained strong, with companies like Zhaojin Mining and Shandong Gold benefiting from a weaker dollar [4] Infrastructure Developments - The establishment of the Xinjiang section of the New Tibet Railway, with a total investment of up to 350 billion RMB, is expected to boost related sectors, leading to stock increases in construction companies [4] - The MSCI announced the addition of 14 new stocks to its China index, including companies like 3SBio and Meituan, indicating potential investment opportunities [6] Emerging Technologies - The low Earth orbit satellite launch pace is accelerating, with multiple successful launches planned for the second half of the year, enhancing China's capabilities in satellite communications [7] - Companies like Interstellar Aerospace Technology are developing AI application satellites and aim to capture a significant market share in optical remote sensing satellites by 2028 [8] Individual Company Strategies - Smoore International is focusing on business transformation, with expectations of improved performance in HNB products following successful launches in Japan [9] - The company is diversifying into aerosol technology for beauty and medical applications, positioning 2025 as a critical year for growth [10]

Group 1 - Southbound funds net bought HKD 6.271 billion in Hong Kong stocks today [1] - Notable net purchases include Alibaba-W at HKD 730 million, Tracker Fund at HKD 683 million, and Xiaomi Group-W at HKD 472 million [1] - Southbound funds have net bought Tencent for 12 consecutive days, totaling HKD 6.47567 billion [1] Group 2 - Significant net sales were observed in SMIC at HKD 426 million, Hua Hong Semiconductor at HKD 335 million, and Hutchison China MediTech at HKD 158 million [1] - Alibaba-W has seen net purchases for 5 consecutive days, amounting to HKD 3.33906 billion [1]

Core Insights - On August 8, 2025, SMIC (00981), Alibaba-W (09988), and Xiaomi Group-W (01810) were the top three companies by trading volume in the Southbound Stock Connect, with trading amounts of 6.668 billion, 2.541 billion, and 2.286 billion respectively [1] - In the Southbound Stock Connect for Shenzhen, SMIC (00981), Xiaomi Group-W (01810), and Alibaba-W (09988) also ranked as the top three, with trading amounts of 4.406 billion, 1.514 billion, and 1.346 billion respectively [1] Southbound Stock Connect (Shanghai) - Top active companies by trading volume: - SMIC (00981): 6.668 billion with a net buy of 0.213 billion - Alibaba-W (09988): 2.541 billion with a net buy of 0.398 billion - Xiaomi Group-W (01810): 2.286 billion with a net buy of 0.547 billion - Tencent Holdings (00700): 1.916 billion with a net buy of 0.424 billion - Huizhou Network (09878): 1.758 billion with a net buy of 0.0758 billion - Hua Hong Semiconductor (01347): 1.125 billion with a net sell of 0.336 billion - Nanjing Panda Electronics (00553): 1.075 billion with a net sell of 0.0252 billion - CSPC Pharmaceutical Group (01093): 1.075 billion with a net sell of 0.133 billion - Dongfang Zhenxuan (01797): 1.024 billion with a net buy of 0.0556 billion - Jing Tai Holdings (02228): 0.956 billion with a net buy of 0.0446 billion [1] Southbound Stock Connect (Shenzhen) - Top active companies by trading volume: - SMIC (00981): 4.406 billion with a net sell of 0.639 billion - Xiaomi Group-W (01810): 1.514 billion with a net sell of 0.0745 billion - Alibaba-W (09988): 1.346 billion with a net buy of 0.333 billion - Tencent Holdings (00700): 1.214 billion with a net sell of 0.319 billion - Hutchison China MediTech (00013): 0.958 billion with a net sell of 0.158 billion - CanSino Biologics (09926): 0.893 billion with a net buy of 0.0202 billion - Zai Lab (09688): 0.768 billion with a net buy of 0.0217 billion - Innovent Biologics (01801): 0.759 billion with a net buy of 0.0745 billion - Fufeng Group (03738): 0.747 billion with a net buy of 0.0315 billion - Tracker Fund of Hong Kong (02800): 0.729 billion with a net buy of 0.0684 billion [1]

Group 1 - The pharmaceutical sector has outperformed the market, with stock prices increasing between 60% to 100% in the first half of the year [1] - The export value of innovative drugs in the first half of the year has already reached the total amount of the previous year [1] - The stock price of CSPC Pharmaceutical Group (01093) has shown strong performance, reaching HKD 10.27, up 6.10% with a trading volume of HKD 14.29 billion [2] Group 2 - Technical indicators for CSPC indicate a bullish trend, with MACD maintaining a buy signal and RSI rising to 61, entering a strong zone [2] - Key price levels for CSPC include a psychological support at HKD 9 and a short-term target at HKD 10.42, with a potential challenge at HKD 11.4 [2] - The performance of related derivatives has shown significant leverage effects, with call warrants outperforming the underlying stock [4] Group 3 - Two notable call warrants for CSPC are available: one with a strike price of HKD 10.88 and a leverage of 3.6 times, and another with a strike price of HKD 10.95 and a leverage of 3.1 times [7] - Investors are considering whether the recent price increase for CSPC is a short-term rebound or the start of a medium to long-term trend [9]

Group 1: Company Developments - Huajian Medical has purchased 5.190 Ethereum (ETH) for a total of 149 million HKD, with an average price of 28.80 HKD (3.661 USD) per ETH, aiming to become a leading listed company in Ethereum reserves [6][8][13] - The company has established a strategic partnership with HashKey Exchange to enhance its digital asset management and capital upgrade, focusing on the development of a crypto treasury and Web3 medical asset trading ecosystem [8][13] - Huajian Medical's Chief Strategy Officer expressed the company's ambition to become a new giant in the Ethereum treasury space, enhancing its ability to withstand market volatility and benefit shareholders in the long term [13] Group 2: Industry Trends - The new energy vehicle sector showed strong performance in July, with 19 manufacturers achieving wholesale sales exceeding 10,000 units, representing 92.1% of total new energy vehicle sales [15][16] - Notable stock performances in the new energy vehicle sector included Dongfeng Group rising by 8.55%, Xiaopeng Motors by 3.12%, and NIO by 2.98% [16][20] - Xiaopeng Motors announced the upcoming launch of its first super electric vehicle model, the Xiaopeng X9, expected to be released in the fourth quarter, following extensive testing across 20 countries and 330 cities [20]